Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Abstract Six of 796 patients treated with intensive combination chemotherapy for small cell carcinoma of the lung developed overt acute nonlymphocytic leukemia (ANLL) (three patients) or preleukemia with severe refractory cytopenia and clonal cytogenetic abnormalities in bone marrow cells (three patients). The latent period to development of preleukemia or leukemia was less than two years in four of the six patients. The cumulative risk of preleukemia and leukemia according to a Kaplan-Meier estimate was 14.0% +/- 6.9% (mean +/- SE) four years after the start of treatment. The relative risk of overt ANLL was 77, since three cases were observed v 0.039 cases expected, based on the age- and sex- specific incidence of acute nonlymphocytic leukemia in the general Danish population. The risk of secondary solid tumors was not increased. The possible causes of the exceptionally early appearance and very high cumulative risk of leukemic complications found in the present study, as compared to previous experience in other malignant diseases, is discussed, including the implications for future therapy of patients with small cell lung cancer.

Download Full-text

Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Blood ◽

10.1182/blood.v66.6.1393.bloodjournal6661393 ◽

1985 ◽

Vol 66 (6) ◽

pp. 1393-1397

Author(s):

J Pedersen-Bjergaard ◽

K Osterlind ◽

M Hansen ◽

P Philip ◽

AG Pedersen ◽

...

Keyword(s):

Cell Carcinoma ◽

Solid Tumors ◽

Small Cell Carcinoma ◽

Bone Marrow Cells ◽

Cumulative Risk ◽

Small Cell ◽

Acute Nonlymphocytic Leukemia ◽

Kaplan Meier ◽

Future Therapy ◽

Very High

Six of 796 patients treated with intensive combination chemotherapy for small cell carcinoma of the lung developed overt acute nonlymphocytic leukemia (ANLL) (three patients) or preleukemia with severe refractory cytopenia and clonal cytogenetic abnormalities in bone marrow cells (three patients). The latent period to development of preleukemia or leukemia was less than two years in four of the six patients. The cumulative risk of preleukemia and leukemia according to a Kaplan-Meier estimate was 14.0% +/- 6.9% (mean +/- SE) four years after the start of treatment. The relative risk of overt ANLL was 77, since three cases were observed v 0.039 cases expected, based on the age- and sex- specific incidence of acute nonlymphocytic leukemia in the general Danish population. The risk of secondary solid tumors was not increased. The possible causes of the exceptionally early appearance and very high cumulative risk of leukemic complications found in the present study, as compared to previous experience in other malignant diseases, is discussed, including the implications for future therapy of patients with small cell lung cancer.

Download Full-text

Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung

Lung Cancer ◽

10.1016/s0169-5002(86)80767-x ◽

1986 ◽

Vol 2 (4) ◽

pp. 268

Keyword(s):

Cell Carcinoma ◽

Solid Tumors ◽

Small Cell Carcinoma ◽

Small Cell ◽

Acute Nonlymphocytic Leukemia ◽

Intensive Chemotherapy

Download Full-text

Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study

Radiation Oncology ◽

10.1186/s13014-019-1415-9 ◽

2019 ◽

Vol 14 (1) ◽

Cited By ~ 1

Author(s):

Baoqing Chen ◽

Han Yang ◽

Huali Ma ◽

Qiaoqiao Li ◽

Bo Qiu ◽

...

Keyword(s):

Prognostic Factors ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Small Cell ◽

Therapeutic Modality ◽

Cancer Center ◽

Lesion Length ◽

Carcinoma Of The Esophagus ◽

Kaplan Meier ◽

Ecog Ps

Abstract Background Small cell carcinoma of the esophagus (SCCE) is characterized by its progressive feature and poor prognosis. There is no consensus on a standard therapeutic modality for SCCE. In this study, we aimed to characterize the outcomes of primary SCCE patients treated by radiation therapy as part of treatment and investigate prognostic factors. Methods We retrospectively analyzed the data of 42 SCCE patients who were treated by RT as part of treatment at the Sun Yat-sen University Cancer Center from 2001 to 2014. The Kaplan-Meier and log-rank method were used to analyze survival. Cox’s hazard regression model was applied to determine prognostic factors. Results Of the 42 enrolled patients, 25 had limited disease (LD) and 17 with extensive disease (ED). The overall response rate (CR + PR) was 60.0% (21/35). The median overall survival time (OS) for whole and LD group were 12.9 and 36.8 months. The 1-, 3- and 5-year OS rates of the whole cohort were 64.9, 31.3, and 13.9%, respectively. OS was significantly longer in patients with ECOG performance score (ECOG PS) < 2 (p = 0.001), lesion length ≤ 5 cm (p = 0.001), and LD (p = 0.049). In the patients with LD, multivariate analysis indicated that combined with chemotherapy (P = 0.046) and higher radiation dose (P = 0.027) predicted better prognosis in OS. The overall rate of grade 3–4 toxicities in the whole cohort was 37.5%. In total, 65% (17/26) patients with recurrent disease died with the metastasis with or without the primary recurrence. Conclusion RT was one of the effective and safe treatments for locoregional control of SCCE. Lower ECOG PS score, shorter lesion length, treated with chemotherapy, and a higher dose of RT were identified as favorable independent prognostic factors.

Download Full-text

Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report

Cancer Chemotherapy and Pharmacology ◽

10.1007/bf02897207 ◽

1990 ◽

Vol 26 (3) ◽

pp. 235-236 ◽

Cited By ~ 6

Author(s):

Daniel Brenez ◽

Jacques Devriendt ◽

Christine Lenclud ◽

Jacqueline Schmerber

Keyword(s):

Case Report ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Small Cell ◽

Acute Nonlymphocytic Leukemia

Download Full-text

Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report

Lung Cancer ◽

10.1016/0169-5002(91)90223-s ◽

1991 ◽

Vol 7 (3) ◽

pp. 203

Keyword(s):

Case Report ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Small Cell ◽

Acute Nonlymphocytic Leukemia

Download Full-text

Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung.

Journal of Clinical Oncology ◽

10.1200/jco.1984.2.5.385 ◽

1984 ◽

Vol 2 (5) ◽

pp. 385-390 ◽

Cited By ~ 47

Author(s):

L Y Chak ◽

B I Sikic ◽

M A Tucker ◽

R C Horns ◽

R S Cox

Keyword(s):

Relative Risk ◽

Acute Leukemia ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Confidence Limit ◽

Small Cell ◽

Acute Nonlymphocytic Leukemia ◽

Actuarial Risk

A group of 158 patients with small cell carcinoma of the lung were followed for 174.5 person-years of observation to determine the risk of acute leukemia. Three cases of acute nonlymphocytic leukemia were observed at 2.3, 2.7, and 3.0 years. The relative risk of developing leukemia was 316 (95% confidence limit, 76-818) and the actuarial risk was 25% +/- 13% at 3.1 years. The relative risk for leukemia was significantly increased in these patients (p less than 0.0001).

Download Full-text